(EDIT) Editas Medicine - Overview
Stock: CRISPR, Gene, Editing, Therapeutics
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 106% |
| Relative Tail Risk | -17.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.81 |
| Alpha | 3.16 |
| Character TTM | |
|---|---|
| Beta | 2.217 |
| Beta Downside | 1.734 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.46% |
| CAGR/Max DD | -0.47 |
Description: EDIT Editas Medicine January 02, 2026
Editas Medicine Inc. (NASDAQ: EDIT) is a clinical-stage biotechnology firm that builds therapeutic candidates using its proprietary CRISPR-based gene-editing platform. The company originated as Gengine, Inc., rebranded in November 2013, and operates out of Cambridge, Massachusetts. Its current collaborations include a research partnership with Juno Therapeutics to create alpha-beta T-cell therapies for both solid and liquid tumors.
Key operational metrics as of the latest quarter: cash and cash equivalents of roughly $550 million, providing a runway of about 18 months at current burn rates; a pipeline that includes EDIT-101 (a CRISPR-based treatment for Leber congenital amaurosis) in Phase 1/2 and EDIT-301 (targeting sickle-cell disease) slated for IND filing in 2024. The broader CRISPR therapeutics market is projected to grow at a CAGR of ~15 % through 2030, driven by accelerating regulatory approvals and expanding indications, while competitive pressure from peers such as Intellia Therapeutics and CRISPR Therapeutics remains a material risk factor.
For a deeper, data-driven assessment of EDIT’s valuation relative to sector benchmarks, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -199.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.90 > 0.02 and ΔFCF/TA -31.15 > 1.0 |
| NWC/Revenue: 248.2% < 20% (prev 321.9%; Δ -73.69% < -1%) |
| CFO/TA -0.89 > 3% & CFO -179.6m > Net Income -199.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.1m) vs 12m ago 9.22% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 17.53% > 50% (prev 18.85%; Δ -1.33% > 0%) |
| Interest Coverage Ratio: -27.46 > 6 (EBITDA TTM -176.3m / Interest Expense TTM 6.63m) |
Altman Z'' -15.00
| A: 0.57 (Total Current Assets 176.9m - Total Current Liabilities 61.8m) / Total Assets 201.8m |
| B: -8.04 (Retained Earnings -1.62b / Total Assets 201.8m) |
| C: -0.69 (EBIT TTM -182.2m / Avg Total Assets 264.7m) |
| D: -8.62 (Book Value of Equity -1.62b / Total Liabilities 188.3m) |
| Altman-Z'' Score: -36.16 = D |
Beneish M 1.00
| DSRI: 85.91 (Receivables 8.13m/126.0k, Revenue 46.4m/61.8m) |
| GMI: 0.95 (GM 95.07% / 90.46%) |
| AQI: 0.92 (AQ_t 0.01 / AQ_t-1 0.02) |
| SGI: 0.75 (Revenue 46.4m / 61.8m) |
| TATA: -0.10 (NI -199.8m - CFO -179.6m) / TA 201.8m) |
| Beneish M-Score: 66.48 (Cap -4..+1) = D |
What is the price of EDIT shares?
Over the past week, the price has changed by -8.54%, over one month by -14.95%, over three months by -32.34% and over the past year by +40.00%.
Is EDIT a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 8
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the EDIT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.4 | 198.4% |
| Analysts Target Price | 5.4 | 198.4% |
| ValueRay Target Price | 1.3 | -28.6% |
EDIT Fundamental Data Overview February 03, 2026
P/B = 14.3674
Revenue TTM = 46.4m USD
EBIT TTM = -182.2m USD
EBITDA TTM = -176.3m USD
Long Term Debt = 19.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.09m USD (from shortTermDebt, last quarter)
Debt = 19.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -146.0m USD (from netDebt column, last quarter)
Enterprise Value = 48.3m USD (194.3m + Debt 19.7m - CCE 165.6m)
Interest Coverage Ratio = -27.46 (Ebit TTM -182.2m / Interest Expense TTM 6.63m)
EV/FCF = -0.27x (Enterprise Value 48.3m / FCF TTM -180.7m)
FCF Yield = -374.4% (FCF TTM -180.7m / Enterprise Value 48.3m)
FCF Margin = -389.6% (FCF TTM -180.7m / Revenue TTM 46.4m)
Net Margin = -430.8% (Net Income TTM -199.8m / Revenue TTM 46.4m)
Gross Margin = unknown ((Revenue TTM 46.4m - Cost of Revenue TTM 2.29m) / Revenue TTM)
Tobins Q-Ratio = 0.24 (Enterprise Value 48.3m / Total Assets 201.8m)
Interest Expense / Debt = 12.21% (Interest Expense 2.40m / Debt 19.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -143.9m (EBIT -182.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.86 (Total Current Assets 176.9m / Total Current Liabilities 61.8m)
Debt / Equity = 1.46 (Debt 19.7m / totalStockholderEquity, last quarter 13.5m)
Debt / EBITDA = 0.83 (negative EBITDA) (Net Debt -146.0m / EBITDA -176.3m)
Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -146.0m / FCF TTM -180.7m)
Total Stockholder Equity = 57.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -75.51% (Net Income -199.8m / Total Assets 201.8m)
RoE = -348.5% (Net Income TTM -199.8m / Total Stockholder Equity 57.3m)
RoCE = -236.6% (out of range, set to none) (EBIT -182.2m / Capital Employed (Equity 57.3m + L.T.Debt 19.7m))
RoIC = -251.0% (out of range, set to none) (NOPAT -143.9m / Invested Capital 57.3m)
WACC = 13.67% (E(194.3m)/V(213.9m) * Re(14.08%) + D(19.7m)/V(213.9m) * Rd(12.21%) * (1-Tc(0.21)))
Discount Rate = 14.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.00%
Fair Price DCF = unknown (Cash Flow -180.7m)
EPS Correlation: 50.10 | EPS CAGR: 44.05% | SUE: 1.23 | # QB: 1
Revenue Correlation: -2.77 | Revenue CAGR: -12.54% | SUE: 0.14 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.34 | Chg30d=-0.036 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.14 | Chg30d=-0.076 | Revisions Net=-1 | Growth EPS=+41.8% | Growth Revenue=-29.5%